Analyst Reco. Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Real-time Estimate Cboe BZX Other stock markets 02:53:13 2024-05-20 pm EDT			5-day change	1st Jan Change
38.55 ^USD	+3.32%		-0.90%	-24.00%

May. 16	Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	MT
May. 16	Sector Update: Health Care Stocks Ease Thursday Afternoon	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Adjusts Ionis Pharmaceuticals Price Target to $82 From $85, Maintains Overweight Rating	May. 08	MT
Ionis Pharmaceuticals Insider Sold Shares Worth $256,277, According to a Recent SEC Filing	May. 07	MT
Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform	Apr. 10	MT
Oppenheimer Raises Ionis Pharmaceuticals' Price Target to $75 From $72, Maintains Outperform Rating	Apr. 09	MT
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $72 From $65, Maintains Outperform Rating	Mar. 06	MT
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating	Feb. 26	MT
JPMorgan Chase Adjusts Price Target on Ionis Pharmaceuticals to $55 From $52, Maintains Neutral Rating	Feb. 01	MT
RBC Lifts Price Target on Ionis Pharmaceuticals to $70 From $65, Says Survey Suggests Wainua Launch May Surprise to Upside; Outperform Kept	Jan. 26	MT
Piper Sandler Adjusts Ionis Pharmaceuticals' Price Target to $62 From $60, Maintains Overweight Rating	Jan. 18	MT
BofA Securities Upgrades Ionis Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $62 From $52	Jan. 02	MT
Stifel Adjusts Price Target on Ionis Pharmaceuticals to $50 From $45, Maintains Hold Rating	Dec. 18	MT
Goldman Sachs Raises Price Target on Ionis Pharmaceuticals to $28 From $25, Maintains Sell Rating	Nov. 03	MT
Morgan Stanley Adjusts Price Target on Ionis Pharmaceuticals to $48 From $45, Maintains Equalweight Rating	Nov. 03	MT
BofA Securities Upgrades Ionis Pharmaceuticals to Neutral From Underperform	23-10-23	MT
Raymond James Initiates Ionis Pharmaceuticals With Strong Buy Rating, Price Target is $63	23-09-29	MT
Morgan Stanley Adjusts Price Target on Ionis Pharmaceuticals to $45 From $42, Maintains Equalweight Rating	23-09-27	MT
Fed Rate Outlook Lifts Exchange-Traded Funds, Equity Futures Premarket Wednesday	23-08-09	MT
Citigroup Upgrades Ionis Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $60 From $36	23-07-31	MT
Barclays Adjusts Price Target on Ionis Pharmaceuticals to $37 From $40, Maintains Equalweight Rating	23-05-04	MT
Citigroup Upgrades Ionis Pharmaceuticals to Neutral From Sell, Raises Price Target to $36 From $30	23-05-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Analyst Reco.

Filters